Key Performance
More- Earnings Score: N/A
- Momentum Score: 34
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Neumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to achieve primary endpoints for major depressive disorder treatment, leading the company to discontinue the program. The company is refocusing on three other clinical programs (NMRA-511, NMRA-898, and NMRA-215) and implementing a 35% workforce reduction to extend cash runway into Q3 2027.
06/15/2026, 8:00 AM • GlobeNewswire
The Schall Law Firm is investigating Neumora Therapeutics, Inc. (NASDAQ: NMRA) on behalf of investors for potential securities law violations. The investigation focuses on whether the company issued false or misleading statements or failed to disclose material information to investors.
03/19/2026, 7:27 PM • Benzinga
Neumora Therapeutics announced it will host a conference call on March 30, 2026, to report Q4 and full year 2025 financial results and provide a business update. The clinical-stage biopharmaceutical company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including consolidated topline readouts for KOASTAL-2 and -3 trials anticipated in Q2 2026.
03/16/2026, 7:00 AM • GlobeNewswire
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Neumora Therapeutics, a clinical-stage biopharmaceutical company, announced it will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including KOASTAL-2 and -3 trials anticipated for Q2 2026 readout. Additionally, positive Phase 1b results from NMRA-511 in Alzheimer's disease agitation showed a clinically meaningful 15.7-point reduction on the CMAI total score.
02/04/2026, 7:00 AM • GlobeNewswire
Top 3 Biotech Stocks Capitalizing on the AI Revolution
Three clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.
11/18/2025, 1:02 PM • Investing
Neumora Therapeutics to Host Virtual R&D Day on October 27
Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, highlighting its pipeline of novel neurological treatments, including a potential NLRP3 inhibitor for obesity and a vasopressin receptor antagonist for Alzheimer's disease agitation.
10/01/2025, 7:00 AM • GlobeNewswire
Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
Neumora Therapeutics is initiating a Phase 1 clinical study for NMRA-861, a novel brain disease treatment with potential best-in-class pharmacology and no observed convulsions in pre-clinical studies.
07/23/2025, 7:00 AM • GlobeNewswire
Neumora Therapeutics initiated a Phase 1 clinical study of NMRA-861, a positive allosteric modulator targeting M4 muscarinic receptors for potential schizophrenia treatment. The study aims to evaluate safety, tolerability, and pharmacokinetics in healthy adults and those with stable schizophrenia.
07/09/2025, 7:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.